Vivoryon Therapeutics

Vivoryon Therapeutics is a clinical-stage biotech company based in Halle, Germany, with a 25+ year history. The company is developing innovative small molecule drugs, primarily targeting diabetic kidney disease (DKD) with its lead candidate, varoglutamstat, a first-in-class QPCT/L inhibitor. Under the leadership of CEO/CMO Dr. Frank Weber, Vivoryon is pursuing a precision medicine strategy in a large, underserved market with significant unmet need. The company's success hinges on the clinical and regulatory progress of its lead asset.

Small molecule platform focused on modulating the activity and stability of pathologically relevant proteins, with core expertise in glutaminyl cyclase (QPCT/L) inhibition.

The DKD treatment landscape is evolving with established drug classes (SGLT2i, GLP-1 RA) and new mechanisms in development. Vivoryon's varoglutamstat, targeting QPCT/L to reduce inflammation/fibrosis, represents a novel approach but will need to demonstrate superior or complementary efficacy to compete in a future combination therapy paradigm.